EU validates market application for GSK blood cancer drug

By Frank Prenesti

GSK said the European Medicines Agency had validated its marketing authorisation application for momelotinib, a potential new oral treatment for the blood cancer myelofibrosis after meeting key endpoints in a Phase 3 trial.
Momelotinib has a differentiated mechanism of action, with inhibitory ability which could address the “significant” medical needs of myelofibrosis patients with anaemia, the UK pharmaceutical company said on Friday.

Myelofibrosis is a rare blood cancer characterised by constitutional symptoms, an enlarged spleen and progressive anaemia. It affects around 20,000 patients in the US, with about 40% of patients already anaemic at the time of diagnosis and nearly all patients estimated to develop anaemia eventually.

Patients will often require transfusions, and more than 30% will discontinue treatment due to anaemia.

“Anaemia and transfusion dependence strongly correlate with poor prognosis and shortened survival,” GSK said.

Reporting by Frank Prenesti for Sharecast.com

Featured News

This Week’s Most Read

Wealth DFM